Literature DB >> 8897454

P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

R Bültmann1, H Wittenburg, B Pause, G Kurz, P Nickel, K Starke.   

Abstract

Effects of suramin and five analogs or fragments of suramin were studied on contractions of the rat vas deferens elicited by alpha, beta-methylene ATP (alpha, beta-MeATP; mediated by P2X-purinoceptors), relaxations of the carbachol-precontracted guinea-pig taenia coli elicited by adenosine 5'-O-(2-thiodiphosphate) (ADP beta S; mediated by P2Y-purinoceptors), and the degradation of ATP by rat vas deferens tissue. One compound, NF023, differed from suramin by removal of two p-methylbenzamido groups, whereas another, BSt101, differed from NF023 by additional removal of the three sulphonate residues from one of the terminal naphthalene rings. The compounds all shifted the concentration-response curve of alpha, beta-MeATP in the rat vas deferens to the right and simultaneously increased the maximum of the curve. Where three concentrations were tested, the Arunlakshana-Schild regression was linear, and the slope did not differ from 1. The apparent Kd values were between 1 and 3672 microM. In the guinea-pig taenia coli, the compounds shifted the concentration-response curve of ADP beta S to the right in a parallel manner, but in the one case where three concentrations were tested, the slope of the Arunlakshana-Schild regression was lower than 1. Apparent Kd values were between 10 and 786 microM. The removal of ATP from the medium by vas deferens tissue was decreased only by suramin, NF023 and BSt101, with IC25% values between 170 and 590 microM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897454     DOI: 10.1007/BF00168442

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Effects of suramin on the concentration--response relationship of alpha, beta-methylene ATP on the mouse vas deferens.

Authors:  A G Blakeley; J E Brockbank; S S Kelly; S A Petersen
Journal:  J Auton Pharmacol       Date:  1991-02

Review 2.  Fitting curves to data using nonlinear regression: a practical and nonmathematical review.

Authors:  H J Motulsky; L A Ransnas
Journal:  FASEB J       Date:  1987-11       Impact factor: 5.191

3.  P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates.

Authors:  R Bültmann; B Pause; H Wittenburg; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

4.  P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

Authors:  R Bültmann; H Wittenburg; B Pause; G Kurz; P Nickel; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

5.  Suramin analogs, divalent cations and ATP gamma S as inhibitors of ecto-ATPase.

Authors:  M W Beukers; C J Kerkhof; M A van Rhee; U Ardanuy; C Gurgel; H Widjaja; P Nickel; A P IJzerman; W Soudijn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

6.  Structure Activity Relationships for Derivatives of Adenosine-5'-Triphosphate as Agonists at P(2) Purinoceptors: Heterogeneity Within P(2X) and P(2Y) Subtypes.

Authors:  Geoffrey Burnstock; Bilha Fischer; Charles H V Hoyle; Michel Maillard; Airat U Ziganshin; Antonia L Brizzolara; Amy von Isakovics; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  2004-10-05       Impact factor: 4.360

7.  Two relaxation-mediating P2-purinoceptors in guinea-pig taenia caeci.

Authors:  O Dudeck; R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

8.  Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens.

Authors:  B S Khakh; A Michel; P P Humphrey
Journal:  Eur J Pharmacol       Date:  1994-10-03       Impact factor: 4.432

9.  Blockade of P2X-purinoceptors by trypan blue in rat vas deferens.

Authors:  R Bültmann; M Trendelenburg; K Starke
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Evans blue blocks P2X-purinoceptors in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

View more
  16 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

2.  A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction.

Authors:  Jamshed Iqbal; Petra Vollmayer; Norbert Braun; Herbert Zimmermann; Christa E Müller
Journal:  Purinergic Signal       Date:  2005-12-03       Impact factor: 3.765

3.  Measuring ion channels on solid supported membranes.

Authors:  Patrick Schulz; Benjamin Dueck; Alexandre Mourot; Lina Hatahet; Klaus Fendler
Journal:  Biophys J       Date:  2009-07-08       Impact factor: 4.033

4.  P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue.

Authors:  H Wittenburg; R Bültmann; B Pause; C Ganter; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

5.  Cannabinoid receptor agonists potentiate action potential-independent release of GABA in the dentate gyrus through a CB1 receptor-independent mechanism.

Authors:  Mackenzie E Hofmann; Chinki Bhatia; Charles J Frazier
Journal:  J Physiol       Date:  2011-06-06       Impact factor: 5.182

6.  P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates.

Authors:  R Bültmann; B Pause; H Wittenburg; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

7.  P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

Authors:  R Bültmann; H Wittenburg; B Pause; G Kurz; P Nickel; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

8.  8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Authors:  Joanna Lecka; Irina Gillerman; Michel Fausther; Mabrouka Salem; Mercedes N Munkonda; Jean-Philippe Brosseau; Christine Cadot; Mireia Martín-Satué; Pedro d'Orléans-Juste; Eric Rousseau; Donald Poirier; Beat Künzli; Bilha Fischer; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases).

Authors:  Younis Baqi; Stefanie Weyler; Jamshed Iqbal; Herbert Zimmermann; Christa E Müller
Journal:  Purinergic Signal       Date:  2008-06-05       Impact factor: 3.765

10.  Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds.

Authors:  Carsten Hoffmann; Petra Heine; Gabi Pradel; Yong-Chul Kim; Kenneth A Jacobson; Herbert Zimmermann
Journal:  Drug Dev Res       Date:  2001-01-24       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.